---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Expected outcomes of therapy"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Expected outcomes of therapy. Topics: OPERA-01 planned primary endpoint, OPERA-01 stated rationale and expected benefit, Company statement of the OPERA-01 design objective, Observed palazestrant monotherapy outcomes and stated expected benefit (OP-1250-001), and 12 further topics. 16 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### OPERA-01 planned primary endpoint

> “The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.7-2"></a>

### OPERA-01 stated rationale and expected benefit

> “More effective ETs that can overcome resistance are needed to improve clinical outcomes and maintain quality of life by delaying chemotherapy.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.7-3"></a>

### Company statement of the OPERA-01 design objective

> “OPERA-01 Phase 3 monotherapy trial designed to show superior efficacy in ESR1 mutant and ESR1 wild-type tumors”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.7-4"></a>

### Observed palazestrant monotherapy outcomes and stated expected benefit (OP-1250-001)

> “In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall.”
> “Palazestrant could result in prolongation of time on endocrine therapy, thereby increasing time to disease progression and delaying the transition to cytotoxic chemotherapy.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.2.2.7-5"></a>

### Standard endocrine therapy outcomes in the EMERALD control arm

> “Accordingly, 6-month PFS rates were 34.3% (95% CI, 27.2 to 41.5) versus 20.4% (95% CI, 14.1 to 26.7) for the elacestrant versus SOC arms, respectively, in all patients and 40.8% (95% CI, 30.1 to 51.4) versus 19.1% (95% CI, 10.5 to 27.8), respectively, in patients with ESR1 mutation.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.7-6"></a>

### Fulvestrant outcomes by duration of prior CDK4/6 inhibitor (EMERALD)

> “In those patients who received fulvestrant, the mPFS ranged from 1.9 to 2.1 months across the subgroups evaluated based on prior ET+CDK4/6i duration”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.7-7"></a>

### Standard endocrine therapy and imlunestrant outcomes in ESR1-mutated disease (EMBER-3)

> “Among 256 patients with ESR1 mutations, the median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.7-8"></a>

### Fulvestrant and vepdegestrant outcomes in ESR1-mutated disease (VERITAC-2)

> “Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.7-9"></a>

### Fulvestrant control arm outcomes in a PIK3CA wild-type population (VIKTORIA-1)

> “The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.2.2.7-10"></a>

### Fulvestrant control arm outcomes after an aromatase inhibitor with or without a CDK4/6 inhibitor (CAPItello-291)

> “Overall, 708 patients underwent randomization; 289 patients (40.8%) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer. In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.2.2.7-11"></a>

### Fulvestrant with and without abemaciclib after progression on a CDK4/6 inhibitor (postMONARCH)

> “At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37%”

Source: [Kalinsky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/)

<a id="topic-2.2.2.7-12"></a>

### Real-world progression-free survival with second-line therapy after first-line CDK4/6 inhibitor (systematic review)

> “The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”
> “The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.2.7-13"></a>

### Real-world progression-free survival with second-line therapy in the United States

> “The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.2.7-14"></a>

### Real-world second-line progression-free survival by treatment group in a European cohort

> “Median rwPFS-2L was 5.0 months for endocrine monotherapy ( n = 27), 7.0 months for targeted therapies ( n = 65), 7.4 months for capecitabine ( n = 12), and 8.7 months for other chemotherapy agents ( n = 21).”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

<a id="topic-2.2.2.7-15"></a>

### Real-world time to next treatment with oral SERD monotherapy in ESR1-mutated disease

> “The median TTNT was 6.4 months, and the time-to-treatment-discontinuation was 4.6 months. In those with ≤1 prior lines of metastatic therapy, the TTNT was 8.8 months, compared with 6.0 months in the third-line setting.”

Source: [Lloyd et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770935/)

<a id="topic-2.2.2.7-16"></a>

### Real-world time to next treatment with elacestrant by prior lines of endocrine therapy

> “Median TTNT (mTTNT) was 8.2 months [95% confidence interval (CI), 6.3–13.0] in patients with 1 to 2 prior lines and 7.5 months (95% CI, 7.1–9.9) in those with ≥3 prior lines of ET.”

Source: [Rugo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770937/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
